自2020年始，药通中国论坛系列活动已成功举办16届，招募包括医药、医疗器械、基金、生物园区在内的海内外医疗创新企业，聚集海内外医药及投融资界顶尖BD与管理人员，为项目交流搭建高效的沟通渠道，为资产交易创造宝贵机会。
本次药通中国秋季论坛将举行三天（中国时间2024年9月24日至25日（现场直播）和27日（录播VoD）。以下是论坛日程表及9月24日下午—韩国创新产品路演公司介绍。
Atheon Bio is revolutionizing immune-oncology by pushing the limits of what was once thought impossible, bringing the treatments to solid cancer patients worldwide. We introduce an innovative therapeutic strategy to address the challenge faced by solid cancer patients who do not benefit from existing immuneoncology treatments, particularly those resistant to checkpoint inhibitors.
Novacell Technology Inc. is a biotech company focusing on the development of immunotherapeutic agents for chronic inflammatory and autoimmune diseases. Novacell Technology sets the company aside from other companies in the inflammatory diseases treatment category through methodology, pro-resolution strategy. The pro-resolution reinforcement strategy is driving a paradigm shift in the treatment of inflammatory diseases due to reduced drawbacks and increased advantages. The methodology revolves around targeting of FPR2 (Formyl Peptide Receptor 2)–a prototypical pro-resolving GPCR with Lipoxin-A4 as a ligand–with PEPTIROID (PEPTIde Resolving Overload of Inflammatory/Immune Diseases), Novacell Technology’s own peptide product line.
As a leading pharmaceutical company in South Korea, Ildong Pharmaceutical Co. is dedicated to the development and supply of high-quality pharmaceutical products that contribute to global health and well-being. The company is committed to growing alongside its customers by offering solutions for disease prevention and continuously innovating to develop new therapies for healthier, happier lives.
Ildong has established a strong reputation with its ethical drug franchise, focusing on treatments for chronic diseases, cancer, antibiotics, and digestive and circulatory drugs. In addition to these offerings, its well-known over-the-counter (OTC) brands, such as Biovita (a probiotics product) and Aronamin (a multivitamin), have garnered customer trust.
The company is actively advancing toward its vision of becoming a global healthcare leader, with new drug pipelines that include Besivo, a hepatitis B therapy and the 28th novel drug in South Korea. Alongside pharmaceutical innovations, Ildong is expanding into health functional foods, medical devices, cosmetics, and beverages.
Aptamer Sciences develops innovative products which bring about many benefits from early diagnosis to the treatment of diseases by utilizing aptamers with high performance. Aptamer Sciences launched the world’s first early diagnosis kit for lung cancer with AptoMIA-based multivariate index assay technology and is expanding the development of diagnostic kits for various diseases in stages through research cooperation with hospitals.
J2H Biotech is a bio-venture company focusing on the development of small-molecule drugs for the treatment of intractable rare diseases.
Kangstem Biotech is a leading biotechnology company in South Korea, primarily focused on stem cell therapies. The company specializes in developing innovative treatments based on stem cell technology, targeting various diseases with unmet medical needs. Kangstem Biotech has been actively advancing its clinical pipelines, including therapies for atopic dermatitis, osteoarthritis, and other degenerative diseases.
Pin Therapeutics is a biotech company that has developed a robust and innovative platform focused on Targeted Protein Degradation (TPD) that is directed towards creating bivalent (PROTAC) & molecular glue degrader (MGD) drugs with a focus in the areas of hematological cancers and solid tumors. Leveraging our advanced proprietary TPD platform, we strive to overcome the existing limitations of cancer treatments and offer patients renewed hope.
ABION, INC, founded in 2007, is a biopharmaceutical company specializing in the development of innovative companion diagnostic-based new drugs that target the first-in-class/best-in-class categories of the global market. With continuous and diligent effort to make a progress, ABION has 81 registered patents, performed 41 government projects and is developing 12 pipelines including 1 pipeline in clinical trial phase II. Lately, we have received national grants from Korea Drug Development Fund (KDDF) for the development of ABN401 and 501. In 2021, ABION is listed in KOSDAQ for further expansion.
